Effective medical treatment for thyroid eye disease, a debilitating condition that can cause sight loss, has been lacking. A recent phase III trial of teprotumumab, an IGF1R antagonist, reports encouraging results and could be a game changer. Here, the trial is put in the context of current management strategies to address this question.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Taylor, P. N. et al. Novel insights into the pathogenesis and non-surgical management of Graves orbitopathy. Nat. Rev. Endocrinol. 16, 104–116 (2020).
Douglas, R. S. et al. Teprotumumab for the treatment of active thyroid eye disease. N. Engl. J. Med. 382, 341–52 (2020).
Crudden, C. et al. Below the surface: IGF-1R therapeutic targeting and its endocytic journey. Cells 8, 1223–1245 (2019).
Smith, T. J. & Janssen, J. Insulin-like growth factor-I receptor and thyroid-associated ophthalmopathy. Endocr. Rev. 40, 236–267 (2018).
Minich, W. B. et al. Autoantibodies to the IGF1 receptor in Graves’ orbitopathy. J. Clin. Endocrinol. Metab. 98, 752–760 (2013).
Smith, T. J. et al. Teprotumumab for thyroid-associated ophthalmopathy. N. Engl. J. Med. 376, 1748–1761 (2017).
Thornton, J., Kelly, S. P., Harrison, R. A. & Edwards, R. Cigarette smoking and thyroid eye disease: a systematic review. Eye 21, 1135–45 (2007).
Krieger, C. C. et al. TSH/IGF-1 receptor cross talk in Graves’ ophthalmopathy pathogenesis. J. Clin. Endocrinol. Metab. 101, 2340–2347 (2016).
Furmaniak, J. et al. OP-08-57 Blocking the TSH receptor with the human monoclonal autoantibody K1-70TM improves Graves’ ophthalmopathy and aids control of advanced follicular thyroid cancer — results of long-term treatment under the first in human single patient expanded use therapy. Eur. Thyroid J. 7, S22 (2018).
Bartalena, L. et al. The 2016 European Thyroid Association/European Group on Graves’ orbitopathy guidelines for the management of Graves’ orbitopathy. Eur. Thyroid J. 5, 9–26 (2016).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no competing interests.
Rights and permissions
About this article
Cite this article
Ludgate, M. Shining a light on thyroid eye disease. Nat Rev Endocrinol 16, 259–260 (2020). https://doi.org/10.1038/s41574-020-0340-1
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41574-020-0340-1
This article is cited by
-
Data mining and analysis of adverse event signals associated with teprotumumab using the Food and Drug Administration adverse event reporting system database
International Journal of Clinical Pharmacy (2024)